FDA Approves Nuplazid (pimavanserin) for Parkinson's Disease Psychosis
FDA approves first drug for hallucinations in Parkinson's disease
The FDA approved Nuplazid (pimavanserin) for hallucinations and delusions associated with Parkinson's disease psychosis. Approval was based …
The FDA approved Nuplazid (pimavanserin) to treat hallucinations and delusions in people with Parkinson's disease psychosis. It is the first…
FDA Approves Nuplazid (pimavanserin) for Parkinson's Disease Psychosis
FDA approves first drug for hallucinations in Parkinson's disease
FDA approved Nuplazid (pimavanserin) for hallucinations and delusions associated with Parkinson's disease psychosis. In a 6-week trial, Nupl…
The FDA approved Nuplazid (pimavanserin) to treat hallucinations and delusions in people with Parkinson's disease psychosis. It is the first…
Research across Parkinson's Disease
Related studies from across the Parkinson's Disease family.
Parkinson's institutionalisation risk 37.2% by 10 years; older age, motor severity, cognition predict
Parkinson's Risk Factors Predict Nursing Home Placement
This meta-analysis of European incidence cohorts (n=1046) found a 37.2% cumulative incidence of institutionalisation by 10 years in people w…
Nearly 4 in 10 people with Parkinson's enter a nursing home within 10 years. Older age, worse motor symptoms, and lower cognitive scores rai…
Wearable devices improve walking speed, dynamic balance, and motor function in patients with Parkinson disease
Wearable Devices Improve Walking Speed in Parkinson's
This meta-analysis of 13 RCTs involving 380 participants found that wearable devices significantly improved walking speed (MD = 0.07), TUGT …
Wearable devices may help people with Parkinson's walk faster and improve balance, a new analysis finds.
Mindfulness-based exercise improves motor function in Parkinson's disease and shows favorable signals in Alzheimer's
Mindfulness exercises may improve motor and cognitive function in Parkinson's
This systematic review and meta-analysis of 28 studies indicates that mindfulness-based exercise, including Tai Chi and yoga, significantly …
Mindfulness-based exercises like Tai Chi and yoga show promise in improving movement and mental clarity for those with Parkinson's and Alzhe…
Fecal microbiota transplantation provides modest short-term improvements in daily motor activities for Parkinson's disease
Fecal transplant shows short term motor gains in Parkinson's disease
This meta-analysis of 318 patients with Parkinson's disease found that fecal microbiota transplantation (FMT) resulted in a notable short-te…
A review of clinical data suggests that fecal transplants may help people with Parkinson's disease perform daily physical tasks better for a…
Long-term particulate matter exposure increases risk of Parkinson's disease by 10% to 18%
Long term air pollution exposure linked to Parkinson's disease risk
This meta-analysis evaluates the association between long-term outdoor air pollution and neurodegenerative diseases. It found a significant …
Long-term exposure to outdoor air pollution like particulate matter is linked to an increased risk of developing Parkinson's disease.
GLP-1 receptor agonists are an emerging research focus for metabolic and inflammatory pathways in Parkinson's disease
GLP-1 receptor agonists show promise for Parkinson's disease research
This bibliometric analysis of 282 articles identifies GLP-1 receptor agonists as a growing research area for Parkinson's disease. Key themes…
New research highlights how GLP-1 medications, often used for metabolic issues, are becoming a major focus in treating Parkinson's disease.
α-Synuclein-lysosome axis central to Parkinson's pathogenesis, systematic review finds
Parkinson's protein and lysosome link may guide new treatments
This systematic review synthesizes molecular evidence that the interplay between α-synuclein and lysosomal function is a central mechanism u…
A review reveals how a protein called α-synuclein and lysosomes interact in Parkinson's, pointing to potential new therapies.
Dynamic gratings serve as tools for diagnosis and treatment evaluation in neuro-ophthalmic conditions
Dynamic gratings help doctors understand and treat eye conditions
This narrative review explores the use of dynamic gratings, such as phase-alternating oscillation and rapid serial visual presentation, to e…
Moving patterns on a screen, called dynamic gratings, offer new ways to study and treat vision issues like glaucoma and diabetic retinopathy…
Reduced Vagus Nerve Cross Sectional Area as a Potential Biomarker in Parkinson Disease
Smaller vagus nerve size linked to Parkinson's disease
Meta-analysis reveals significant reductions in the cross-sectional area of the vagus nerve in patients with Parkinson's disease compared to…
A large review of medical data shows that the vagus nerve is smaller in people with Parkinson's disease, potentially offering a new way to t…
Botulinum toxin type A effectively manages sialorrhea in pediatric and adult neurological disorders
Botulinum toxin helps manage drooling in neurological conditions
This narrative review examines the use of botulinum toxin type A for managing sialorrhea in patients with cerebral palsy and Parkinson's dis…
Newer insights show how botulinum toxin can help children and adults with neurological disorders manage excessive drooling.
TCMQE exercises including Baduanjin, Qigong, and Tai Chi improve motor symptoms and balance in Parkinson's disease
Traditional Chinese medicine exercises may improve Parkinson's disease symptoms
This network meta-analysis of 59 RCTs involving 3,743 patients evaluated various traditional Chinese medicine qigong exercise (TCMQE) modali…
Specific traditional Chinese medicine exercises like Tai Chi and Baduanjin show promise in improving balance, movement, and mood for those w…
Evaluating the Efficacy of GLP-1 Receptor Agonists in Patients with Parkinson's Disease
GLP-1 medications show no motor benefit for Parkinson's patients
A meta-analysis reveals that GLP-1 receptor agonists provide no significant motor or non-motor benefits for patients with idiopathic Parkins…
New data suggests GLP-1 receptor agonists do not improve movement or non-motor symptoms in people with Parkinson's disease.